CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 2390610
• 负责人: MARC L CITRON
• 金额: $ 3.91万
• 依托单位: LONG ISLAND JEWISH MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1982
• 资助国家: 美国
• 起止时间: 1982-04-01 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2390610
• 关键词: Bacillus Calmette Guerin vaccine; Hodgkin's disease; T cell receptor; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adenocarcinoma; analgesia; antineoplastics; autologous transplantation; bladder neoplasm; bone marrow transplantation; breast neoplasms; cachexia; cancer pain; cancer prevention; cancer registry /resource; cancer rehabilitation /care; chemoprevention; chromosome translocation; chronic leukemia; chronic myelogenous leukemia; cis platinum compound; clinical trials; colon neoplasms; colorectal neoplasms; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cystectomy; data collection; doxorubicin; emotional adjustment; environmental adaptation; esophagus neoplasm; etoposide; fluorouracil; gene rearrangement; germ cell neoplasms; hairy cell leukemia; head /neck neoplasm; hormone therapy; human subject; human therapy evaluation; ifosfamide; immunoglobulin genes; immunologic assay /test; immunomodulators; interferon alpha; interleukin 2; leucovorin; levamisole; lung neoplasms; lymph node neoplasm; lymphocytic leukemia; lymphoma; melanoma; metastasis; morphine; multiple myeloma; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer remission /regression; neoplasm /cancer surgery; neoplasm /cancer vaccine; postmenopause; prednisone; prognosis; prostate neoplasms; publications; radioimmunoassay; rectum neoplasms; squamous cell carcinoma; steroid hormone receptor; stomach neoplasms; tamoxifen; tumor antigens; vincristine

This is an application for participation by the Long Island Jewish Medical Center as a primary member institution in the overall research activities of Cancer and Leukemia Group B (CALGB) - the NCI-sponsored consortium for cancer research. CALGB conducts randomized clinical trials requiring large scale case accession for testing new and innovative treatments of various types of human cancers in the adult and comparing the results with the best known standard therapies. In addition, studies on basic science of each cancer under investigation are conducted to improve the understanding of its pathophysiology. Emphasis is placed also on psychosocial as well as epidemiological aspects of each type of cancer. Because any one institution only has relatively small numbers of patients with various types of cancer under study, a consortium such as CALGB of like-minded investigators from 26 academic institutions enables, by pooling their respective patient populations, accession of larger numbers which are sufficient to conduct such studies. LIJ-based oncologists maintained an active role in this research process: (1) by proposing concepts for new studies in various types of cancers; (2) by entering cases to each protocol in a disciplined, systematic manner while strictly adhering to the principles of ethical conduct of research involving human subjects, and (3) by emphasizing availability of this research to segments of our society which may have been neglected in the past - women and minority populations. Treatment of each patient is delivered according to a specific protocol, good quality clinical data are collected throughout the period of each study and submitted to the CALGB Biostatistical Center for appropriate analysis and review. LIJ-based scientists then participate actively in group-wide review and discussion of the pooled data from these studies and in preparation of manuscripts summarizing the significance of these results. Thus, the major objective of developing improved methods of treatment of cancer is served by LIJ's participation in CALGB-sponsored research.

这是长岛犹太人的参与申请 医学中心作为整体研究的主要成员机构 癌症和白血病 B 组 (CALGB) 的活动 - NCI 赞助 癌症研究联盟。 CALGB 进行随机临床 需要大规模病例加入的试验来测试新的和 成人和各种类型人类癌症的创新治疗 将结果与最著名的标准疗法进行比较。 在 此外，对每种正在调查的癌症的基础科学研究 进行这些研究是为了提高对其病理生理学的理解。 重点还放在心理社会和流行病学上 每种类型癌症的各个方面。 因为任何一个机构只有 患有各种类型癌症的患者数量相对较少 一项由 CALGB 等来自 26 个志同道合的研究人员组成的联盟进行的研究 学术机构通过汇集各自的患者来实现 人口，加入足以进行 这样的研究。 LIJ 的肿瘤学家在这方面发挥了积极作用 研究过程：（1）通过提出各种新研究的概念 癌症类型； (2) 通过在每个协议中输入案例 纪律严明、系统化，同时严格遵守原则 涉及人类受试者的研究的道德行为，以及（3） 强调这项研究对我们社会各阶层的可用性 过去可能被忽视的——妇女和少数群体 人口。 每位患者的治疗均按照 特定的方案，自始至终收集高质量的临床数据 每项研究的周期并提交给 CALGB 生物统计 适当分析和审查中心。 当时基于 LIJ 的科学家 积极参与集团范围内的汇总审查和讨论 来自这些研究的数据以及总结手稿的准备 这些结果的意义。 因此，主要目标是 LIJ 致力于开发改进的癌症治疗方法 参与 CALGB 资助的研究。

项目成果

Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B.

胞嘧啶阿糖苷和顺铂治疗晚期乳腺癌。

• DOI: 10.1002/1097-0142(19911015)68:8<1696::aid-cncr2820680807>3.0.co;2-b
• 发表时间: 1991
• 期刊: Cancer
• 影响因子: 6.2
• 作者: Oster,MW;Schilsky,RL;Faraggi,D;Korzun,AH;Perry,M;Moore,A;Kalra,J;Wood,WC;Henderson,IC
• 通讯作者: Henderson,IC

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

• DOI: 10.1182/blood.v58.6.1203.bloodjournal5861203
• 发表时间: 1981-12
• 期刊: Blood
• 影响因子: 20.3
• 作者: K. Rai;J. Holland;O. Glidewell;V. Weinberg;K. Brunner;JP Obrecht;H. Preisler;IW Nawabi;D. Pr

Intracellular zinc in chronic lymphocytic leukemia.

慢性淋巴细胞白血病的细胞内锌。

• DOI: 10.1016/0090-1229(82)90085-x
• 发表时间: 1982
• 期刊: Clinical immunology and immunopathology
• 作者: Kanter,RJ;Rai,KR;Muniz,F;Michael,B;Balkon,J;Sawitsky,A
• 通讯作者: Sawitsky,A